Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes ...(TCA 650 on day 1 and removal on day 29. ...)

    Fasting & Postprandial Glucose  ITCA 650 Dose Arms (continuous daily dose)
                                    ------------------------------------------
                                     10          20          40         80
                                   mcg/day     mcg/day     mcg/day    mcg/day
    --------------------------------------------------------------------------
    Mean FPG at baseline (mg/dL)     161.2       170.5       171.8      145.1
    --------------------------------------------------------------------------
    Mean FPG at end of
     treatment (mg/dL)               155.6       139.4       129.8      116.3
    --------------------------------------------------------------------------
    Change from baseline (mg/dL)      -5.6       -31.1*      -42.0*     -28.8*
    --------------------------------------------------------------------------
    Change in 2-hr PPG at end
     of treatment (mg/dL)            -16.3       -34.7*      -47.1*     -69.6*
    --------------------------------------------------------------------------
    *p = < 0.05

Substantial decreases in FPG and PPG were observed throughout treatment. Decreases in FPG were evident within 24 hours after initiation of treatment, suggesting a rapid and consistent achievement of desired exenatide levels with DUROS delivery. Changes in PPG measured at days 15 and 29 also showed consistent dose-dependent reductions. Changes from baseline in FPG and PPG were statistically significant for the 20 mcg/day, 40 mcg/day and 80 mcg/day doses.

    HbA1c & Body Weight             ITCA 650 Dose Arms (continuous daily dose)
                                    ------------------------------------------
                                     10          20          40        80
                                   mcg/day     mcg/day     mcg/day   mcg/day
    ----------------------------------------------------
'/>"/>
SOURCE  Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
7. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
8. Nile Therapeutics, Inc. Adds to Executive Management Team
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results